Anaemia (grade ≥ 3) · platinum‐sensitive recurrent EOC
Summary of findings 1: PLD with chemotherapy probably leads to higher anaemia (grade ≥ 3) compared with alternative combination chemotherapy (moderate certainty).
1 finding from 1 review
Hand‐foot syndrome (grade ≥ 3) · platinum‐sensitive recurrent EOC
It is very uncertain whether summary of findings 1: PLD with chemotherapy changes hand‐foot syndrome (grade ≥ 3) compared with alternative combination chemotherapy (very low certainty).
1 finding from 1 review
Neurological (grade ≥ 3) · platinum‐sensitive recurrent EOC
It is very uncertain whether summary of findings 1: PLD with chemotherapy changes neurological (grade ≥ 3) compared with alternative combination chemotherapy (very low certainty).
1 finding from 1 review
Dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in scores indicating clinical improvement) at 1‐month (with actual · people with dry eyea
Oral omega‐3 PUFAs plus conventional therapy showed no clear difference in dry eye symptoms, measured using the OSDI score (ranging from 0 to… compared with conventional therapy alone (low certainty).
1 finding from 1 review
Ocular surface staining · people with dry eyea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Aqueous tear production · people with dry eyea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tear film stability · people with dry eyea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in tear osmolarity (measured in mOsmol/L, with reductions in osmolarity indicating clinical improvement) at 1‐month (with actual · people with dry eyea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events at 1‐month · people with dry eyea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Use of ET (≥ 1); all studies · neonates with alloimmune hemolytic disease
It is very uncertain whether intravenous immunoglobulin plus phototherapy changes use of ET (≥ 1); all studies compared with phototherapy alone (very low certainty).
1 finding from 1 review
Use of ET (≥ 1); placebo‐controlled studies · neonates with alloimmune hemolytic disease
Intravenous immunoglobulin plus phototherapy showed no clear difference in use of ET (≥ 1); placebo‐controlled studies compared with phototherapy alone (moderate certainty).
1 finding from 1 review
ETs performed per infant; all studies · neonates with alloimmune hemolytic disease
1 finding from 1 review
ETs performed per infant; placebo‐controlled studies · neonates with alloimmune hemolytic disease
1 finding from 1 review
Use of top‐up transfusion in 1st week of life; all studies · neonates with alloimmune hemolytic disease
Intravenous immunoglobulin plus phototherapy showed no clear difference in use of top‐up transfusion in 1st week of life; all studies compared with phototherapy alone (low certainty).
1 finding from 1 review
Use of top‐up transfusion after 1st week of life; all studies · neonates with alloimmune hemolytic disease
It is very uncertain whether intravenous immunoglobulin plus phototherapy changes use of top‐up transfusion after 1st week of life; all studies compared with phototherapy alone (very low certainty).
1 finding from 1 review
Maximum total serum bilirubin (µmol/L); all studies · neonates with alloimmune hemolytic disease
1 finding from 1 review
All‐cause mortality · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Metformin · people at increased risk for developing type 2 diabetes
2 findings from 1 review
Acarbose · people at increased risk for developing type 2 diabetes
2 findings from 1 review
Repaglinide · people at increased risk for developing type 2 diabetes
2 findings from 1 review